References
- Chegini N, Ma C, Tang XM, Williams RS. Effects of GnRH analogues, ‘add-back’ steroid therapy, antiestrogen and antiprogestins on leiomyoma and myometrial smooth muscle cell growth and transforming growth factor-beta expression. Mol Hum Reprod 2002;8:1071–8
- Donnez J, Jadoul P. What are the implications of myomas on fertility? A need for a debate? Hum Reprod 2002;17:1424–30
- Parker WH. Sustained relief of leiomyoma symptoms by using focused ultrasound surgery. Obstet Gynecol 2007;110:1173 (author reply 1173)
- McCarthy-Keith DM, Malik M, Britten J, et al. Gonadotropin-releasing hormone agonist increases expression of osmotic response genes in leiomyoma cells. Fertil Steril 2011;95:2383–7
- Ravina JH, Bouret JM, Ciraru-Vigneron N, et al. Recourse to particular arterial embolization in the treatment of some uterine leiomyoma. Bull Acad Natl Med 1997;181:233–43 (discussion 244–6)
- Duhan N. Current and emerging treatments for uterine myoma – an update. Int J Womens Health 2011;3:231–41
- Stewart EA. Uterine fibroids and evidence-based medicine – not an oxymoron. N Engl J Med 2012;366:471–3
- Chwalisz K, Perez MC, Demanno D, et al. Selective progesterone receptor modulator development and use in the treatment of leiomyomata and endometriosis. Endocr Rev 2005;26:423–38, Erratum in: Endocr Rev 2005;26:703
- Fiscella K, Eisinger SH, Meldrum S, et al. Effect of mifepristone for symptomatic leiomyomata on quality of life and uterine size: a randomized controlled trial. Obstet Gynecol 2006;108:1381–7
- Donnez J, Tomaszewski J, Vázquez F, et al. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N Engl J Med 2012a;366:421–32
- Donnez J, Tatarchuk TF, Bouchard P, et al. Ulipristal acetate versus placebo for fibroid treatment before surgery. N Engl J Med 2012b;366:409–20
- Higgins JPT, Green S (eds.). Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane Collaboration 2011. Available from: www.cochrane-handbook.org [last accessed Mar 2011]
- Levens ED, Potlog-Nahari C, Armstrong AY, et al. CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstet Gynecol 2008;111:1129–36
- Nieman LK, Blocker W, Nansel T, et al. Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo controlled, phase IIb study. Fertil Steril 2011;95:767–72 .e1
- Engman M, Varghese S, Lagerstedt Robinson K, et al. GSTM1 gene expression correlates to leiomyoma volume regression in response to mifepristone treatment. PLoS One 2013;8:e80114
- Yerushalmi GM, Gilboa Y, Jakobson-Setton A, et al. Vaginal mifepristone for the treatment of symptomatic uterine leiomyomata: an open-label study. Fertil Steril 2014;101:496–500
- Donnez J, Vázquez F, Tomaszewski J, et al. Long-term treatment of uterine fibroids with ulipristal acetate. Fertil Steril 2014;101:1565–73 .e1–18